【摘要】 目的探讨重组人血管内皮抑素联合培美曲塞治疗老年性肺腺癌的临床效果及对患者血清VEGF、T细胞亚群水平的影响。方法将2011年3月~2015年4月于我院确诊的老年性肺腺癌的81例患者纳入研究并随机分组,对照组40例患者采用培美曲塞治疗,观察组41例则联合重组人血管内皮抑素治疗。比较两组的血管内皮生长因子(VEGF)、T细胞亚群(CD4~+T、CD4~+/CD8~+T、CD8~+T)水平改善情况,比较临床疗效及药物骨髓抑制情况。结果与对照组比较,观察组的1年生存率更高,且总有效率更高(P<0.05);患者CD4~+T、CD4~+/CD8~+T等指标水平提高,CD8~+T未变化,VEGF则降低,但观察组改善更显著,且白细胞、血小板、血红蛋白降幅更小(P<0.05)。结论重组人血管内皮抑素联合培美曲塞治疗老年性肺腺癌的效果显著,预后更好,安全可靠,值得推广。更多还原

【Abstract】 Objective To study the clinical curative effect of Recombinant human vascular endothelial inhibition combined with Pemetrexed treating senile pulmonary adenocarcinoma and its influence on serum level of VEGF and T cell subgroup.Methods 81 senile patients with lung adenocarcinoma from March 2011 to April 2015 diagnosed in our hospital were admitted into study and they were randomized into two groups.The control group(n =40) was treated with Pemetrexed,while the observation group(n=41) was treated with Recombinant human vascular endothelial inhibition.Improvement of vascular endothelial growth factor(VEGF) and T cell subgroup(CD4~+T,CD4~+/CD8~+T and CD8~+T) between two groups was compared respectively and clinical curative effect and drug marrow suppression was compared respectively.Results Compared with control group,the observation group′ s survival rate of 1 year and the total effective rate were both higher(P<0.05).The index level of CD4~+T, CD4~+/CD8~+T increased with few changes of CD8~+T and the decrease of VEGF,while the observation group improved more significantly.The level of white blood cell,plateles,hemoglobin cut down more significantly(P<0.05).Conclusion Curative effect of Recombinant human vascular endothelial inhibition combined with pemetrexed treating senile pulmonary adenocarcinoma is distinct,with better prognosis,safe and reliable,which is worthy of promotion.更多还原